Recent studies

In the following is an overview of our currently running studies.

Studies on prostate cancer (PCa)

Name Needed criteria Study goal Study type

Harrow

Hormone therapy

Active Surveillance

Radiotherapy

Operation

Watchfull Waiting

*Newly diagnosed prostate cancer

*Locally limited (including T2c)

*No metastases

The aim of the study is to determine the actual supply, to describe typical patient clientele, to find criteria for indication of an invasive or less invasive procedure and to study disease processes Observation study
Study on Restricted versus (against) Extended lymphadenectomy at PCa

*PCA- middle or high risk

*non suspect bone scintigraphy

*local operable tumor

The aim of the study is to observe  progression free survival (Recidiv free) which is based on the PSA level in a 5-year time period at both treatment groups- we acquire the information by calling the patient or the urologist regularly Prospective (forward-looking) randomized (random classification)
PREFERENCE based randomized study to evaluate the various types of treatments in case of low or medium risk PCA

* PCA- low or early medium risk

*locally limited

*Prostate volume

*PSA

*Gleason score

The aim of the study is to evaluate the benefits and risks of each treatment option at patients with low or early recognized intermediate risk PCa. There are four treatment arms (prostatectomy, radiation therapy, brachytherapy, and active surveillance), when the preferences of the patients can be considered. Besides efficacy, the treatment-associated side effects / complications, and the patients’ quality of life are examined. Prospective (forward-looking) randomized (random classification) takes all 4 treatment options into consideration, thus 11 parts are possible of this study

Extraction of biological material in case of prostate cancer (PCa)

Biobank/Cryoconservation

  • ‘Research Project I’

During the operation we take sample from the ‘prostate bed’ for                        research purposes

  • ‘Research Project II’

We take blood and urine for research purposes

Both research projects are evaluated reliable and safe by the Ethics Committee of Munster.

Studies on renal cell carcinoma

Name Needed criteria Study goal Study type

SWITCH-2

Open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib vs. pazopanib followed by sorafenib therapy in case of advanced/metastatic renal cell carcinoma

Patients with metastatic, advanced renal cell carcinoma, who are not suitable for cytokine therapy and the study medication is indicated as first-line therapy Both sorafenib and pazopanib seem to be effective and reliable treatment in case of advanced kidney cancer. Both medicaments are approved for this indication. No prospective comparative data for advanced kidney cancer (or other indications) is published. The aim of the study is to evaluate the progression-free survival. randomized (random classification into the treatment)